Keros Therapeutics Inc (KROS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 102.14 is considered Overvalued compared with the five-year average of -9.46. The fair price of Keros Therapeutics Inc (KROS) is between 4.59 to 12.03 according to relative valuation method. Compared to the current price of 13.91 USD , Keros Therapeutics Inc By Overvalued By 15.65%.

Relative Value

Fair Zone

4.59-12.03

Current Price：13.91

15.65%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Keros Therapeutics Inc (KROS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Keros Therapeutics Inc (KROS) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 2.96, the current P/B ratio is approximately -63.87% higher. Relative to its 5-year average P/B ratio of 3.71, the current P/B ratio is about -71.14% higher. Keros Therapeutics Inc (KROS) has a Forward Free Cash Flow (FCF) yield of approximately 15.42%. Compared to its 3-year average FCF yield of -6.68%, the current FCF yield is approximately -330.91% lower. Relative to its 5-year average FCF yield of -6.04%, the current FCF yield is about -355.36% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for KROS competitors is 21.80, providing a benchmark for relative valuation. Keros Therapeutics Inc Corp (KROS.O) exhibits a P/S ratio of 102.14, which is 368.5% above the industry average. Given its robust revenue growth of 3575.77%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of KROS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of KROS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is KROS currently overvalued or undervalued?

What is Keros Therapeutics Inc (KROS) fair value?

KROS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Keros Therapeutics Inc (KROS) is between 4.59 to 12.03 according to relative valuation method.

How does KROS's valuation metrics compare to the industry average?

The average P/S ratio for KROS's competitors is 21.80, providing a benchmark for relative valuation. Keros Therapeutics Inc Corp (KROS) exhibits a P/S ratio of 102.14, which is 368.50% above the industry average. Given its robust revenue growth of 3575.77%, this premium appears sustainable.

What is the current P/B ratio for Keros Therapeutics Inc (KROS) as of Mar 03 2026?

As of Mar 03 2026, Keros Therapeutics Inc (KROS) has a P/B ratio of 1.07. This indicates that the market values KROS at 1.07 times its book value.

What is the current FCF Yield for Keros Therapeutics Inc (KROS) as of Mar 03 2026?

As of Mar 03 2026, Keros Therapeutics Inc (KROS) has a FCF Yield of 15.42%. This means that for every dollar of Keros Therapeutics Inc's market capitalization, the company generates 15.42 cents in free cash flow.

What is the current Forward P/E ratio for Keros Therapeutics Inc (KROS) as of Mar 03 2026?

As of Mar 03 2026, Keros Therapeutics Inc (KROS) has a Forward P/E ratio of -9.44. This means the market is willing to pay $-9.44 for every dollar of Keros Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Keros Therapeutics Inc (KROS) as of Mar 03 2026?

As of Mar 03 2026, Keros Therapeutics Inc (KROS) has a Forward P/S ratio of 102.14. This means the market is valuing KROS at $102.14 for every dollar of expected revenue over the next 12 months.

KROS Valuation